CRDF - Cardiff Oncology's Onvansertib Could Possibly End Up Being A Solid Cancer Drug
- Onvansertib along with FOLFIRI and Avastin in a phase 1b/2 study treating second-line KRAS-mutated mCRC patients achieved a 45% objective response rate.
- Response rate for second-line KRAS-mutated mCRC patients remains low for standard of care treatment at roughly around 4%.
- Positive results were achieved in a phase 1/2 study using onvansertib plus decitabine to treat relapsed/refractory acute myeloid leukemia patients with 28% response after only 1 cycle of treatment.
- Cardiff Oncology had $27.8 million in cash and cash equivalents and $2.8 million in clinical trial funding commitments/stockholder's equity as of June 30, 2020; additional public offering to raise nearly $88 million was recently announced.
For further details see:
Cardiff Oncology's Onvansertib Could Possibly End Up Being A Solid Cancer Drug